Global Vaccine Market Size, Share, Trends, Growth, Analysis: By Indication: Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19; By Technology: Recombinant, Toxoid, Conjugate, RNA; By End User: Adult, Children; By Distribution Channel: Hospital and Clinical Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Vaccine Market Overview 
    3.1    Global Vaccine Market Historical Value (2017-2023) 
    3.2    Global Vaccine Market Forecast Value (2024-2032)
4    Global Vaccine Market Landscape*
    4.1    Global Vaccine Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Vaccine Product Landscape
        4.2.1    Analysis by Indication
        4.2.2    Analysis by Technology
5    Global Vaccine Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Vaccine Market Segmentation (2017-2032)
    6.1    Global Vaccine Market (2017-2032) by Indication
        6.1.1    Market Overview  
        6.1.2    Pneumococcal
        6.1.3    Influenza
        6.1.4    DTP
        6.1.5    HPV
        6.1.6    MMR
        6.1.7    COVID-19
    6.2    Global Vaccine Market (2017-2032) by Technology
        6.2.1    Market Overview
        6.2.2    Recombinant
        6.2.3    Toxoid
        6.2.4    Conjugate
        6.2.5    RNA
    6.3    Global Vaccine Market (2017-2032) by End User
        6.3.1    Market Overview
        6.3.2    Adult
        6.3.3    Children
    6.4    Global Vaccine Market (2017-2032) by Distribution Channel
        6.4.1    Market Overview
        6.4.2    Hospital and Clinical Pharmacies
        6.4.3    Retail Pharmacies
        6.4.4    Online Pharmacies
    6.5    Global Vaccine Market (2017-2032) by Region
        6.5.1    Market Overview
        6.5.2    North America 
        6.5.3    Europe
        6.5.4    Asia Pacific
        6.5.5    Latin America
        6.5.6    Middle East and Africa
7    North America Vaccine Market (2017-2032)
    7.1    North America Vaccine Market (2017-2032) by Indication
        7.1.1    Market Overview  
        7.1.2    Pneumococcal
        7.1.3    Influenza
        7.1.4    DTP
        7.1.5    HPV
        7.1.6    MMR
        7.1.7    COVID-19
    7.2    North America Vaccine Market (2017-2032) by Technology
        7.2.1    Market Overview
        7.2.2    Recombinant
        7.2.3    Toxoid
        7.2.4    Conjugate
        7.2.5    RNA
    7.3    North America Vaccine Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Vaccine Market (2017-2032)
    8.1    Europe Vaccine Market (2017-2032) by Indication
        8.1.1    Market Overview  
        8.1.2    Pneumococcal
        8.1.3    Influenza
        8.1.4    DTP
        8.1.5    HPV
        8.1.6    MMR
        8.1.7    COVID-19
    8.2    Europe Vaccine Market (2017-2032) by Technology
        8.2.1    Market Overview
        8.2.2    Recombinant
        8.2.3    Toxoid
        8.2.4    Conjugate
        8.2.5    RNA
    8.3    Europe Vaccine Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Vaccine Market (2017-2032)
    9.1    Asia Pacific Vaccine Market (2017-2032) by Indication
        9.1.1    Market Overview  
        9.1.2    Pneumococcal
        9.1.3    Influenza
        9.1.4    DTP
        9.1.5    HPV
        9.1.6    MMR
        9.1.7    COVID-19
    9.2    Asia Pacific Vaccine Market (2017-2032) by Technology
        9.2.1    Market Overview
        9.2.2    Recombinant
        9.2.3    Toxoid
        9.2.4    Conjugate
        9.2.5    RNA
    9.3    Asia Pacific Vaccine Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America Vaccine Market (2017-2032)
    10.1    Latin America Vaccine Market (2017-2032) by Indication
        10.1.1    Market Overview  
        10.1.2    Pneumococcal
        10.1.3    Influenza
        10.1.4    DTP
        10.1.5    HPV
        10.1.6    MMR
        10.1.7    COVID-19
    10.2    Latin America Vaccine Market (2017-2032) by Technology
        10.2.1    Market Overview
        10.2.2    Recombinant
        10.2.3    Toxoid
        10.2.4    Conjugate
        10.2.5    RNA
    10.3    Latin America Vaccine Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa Vaccine Market (2017-2032)
    11.1    Middle East and Africa Vaccine Market (2017-2032) by Indication
        11.1.1    Market Overview  
        11.1.2    Pneumococcal
        11.1.3    Influenza
        11.1.4    DTP
        11.1.5    HPV
        11.1.6    MMR
        11.1.7    COVID-19
    11.2    Middle East and Africa Vaccine Market (2017-2032) by Technology
        11.2.1    Market Overview
        11.2.2    Recombinant
        11.2.3    Toxoid
        11.2.4    Conjugate
        11.2.5    RNA
    11.3    Middle East and Africa Vaccine Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
    12.1    Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent Analysis
    13.1    Analysis by Type of Patent
    13.2    Analysis by Publication Year
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Patent Age
    13.5    Analysis by CPC Analysis
    13.6    Analysis by Patent Valuation 
    13.7    Analysis by Key Players
14    Grants Analysis
    14.1    Analysis by Year
    14.2    Analysis by Amount Awarded
    14.3    Analysis by Issuing Authority
    14.4    Analysis by Grant Application
    14.5    Analysis by Funding Institute
    14.6    Analysis by NIH Departments
    14.7    Analysis by Recipient Organization 
15    Funding Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Supplier Landscape
    17.1    Merck & Co. Inc.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    GlaxoSmithKline Plc
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Sanofi Aventis
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Novartis AG
        17.4.1    Financial Analysis
        17.4.2    Financial Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Pfizer Inc.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Takeda Pharmaceutical Company Limited
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    DAIICHI SANKYO COMPANY, LIMITED
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Mitsubishi Chemical Group Corporation
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    AstraZeneca
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    MASSACHUSETTS BIOTECHNOLOGY COUNCIL
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Biokangtai
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Serum Institute of India Pvt. Ltd
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    VBI Vaccines Inc 
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Fei Biological 
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Indian Immunologicals Ltd.
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
List not exhaustive
18    Global Vaccine Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)
    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.